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Purpose
The prognosis of patients with colon cancer and para-aortic lymph node metastasis (PALNM)
is poor. We analyzed the prognostic factors of extramesenteric lymphadenectomy for colon
cancer patients with isolated PALNM.  
Materials and Methods
We retrospectively reviewed 49 patients with PALNM who underwent curative resection 
between October 1988 and December 2009.  
Results
In univariate analyses, the 5-year overall survival (OS) and disease-free survival (DFS) rates
were higher in patients with  7 positive para-aortic lymph node (PALN) (36.5% and 27.5%)
than in those with > 7 PALN (14.3% and 14.3%; p=0.010 and p=0.027, respectively), and
preoperative carcinoembryonic antigen (CEA) level > 5 was also correlated with a lower 
5-year OS and DFS rate of 21.5% and 11.7% compared with those with CEA  5 (46.3%
and 41.4%; p=0.122 and 0.039, respectively). Multivariate analysis found that the number
of positive PALN (hazard ratio [HR], 3.291; 95% confidence interval [CI], 1.309 to 8.275;
p=0.011) was an independent prognostic factor for OS and the number of positive PALN
(HR, 2.484; 95% CI, 0.993 to 6.211; p=0.052) and preoperative CEA level (HR, 1.953; 95%
CI, 0.940 to 4.057; p=0.073) were marginally independent prognostic factors for DFS. 
According to our prognostic model, the 5-year OS and DFS rate increased to 59.3% and
53.3%, respectively, in patients with  7 positive PALN and CEA level  5.  
Conclusion
PALN dissection might be beneficial in carefully selected patients with a low CEA level and
less extensive PALNM.  
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Introduction
Isolated para-aortic lymph node (PALN) metastasis
(PALNM) occurs in up to 2% of colorectal cancer (CRC) 
patients and is regarded as a poor prognostic factor [1,2]. 
Although the American Joint Committee on Cancer (AJCC)
staging system classifies CRC with metastasis to PALNs as
M1 disease, the clinical characteristics of it have not been
comprehensively elucidated and there is no consensus on the
treatment strategy for isolated PALNM in CRC [3]. 
The complete response rate in colon cancer patients with
PALNM remains low despite newly developed chemother-
apeutic agents and it is difficult to control the progression of
disease without surgical intervention [1]. In CRC patients
with hepatic or pulmonary metastases, aggressive hepatic or
lung resection has become a standard strategy when R0 
resection can be achieved. However, the role of PALN dis-
section (PALND) has not been established due to its low 
incidence, postoperative morbidity, and advances in the field
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of chemotherapy.
Previously, we reported that the oncologic outcomes of
colon cancer with isolated PALNM were comparable with
outcomes of metastatectomy for liver metastasis and sug-
gested that upfront primary tumor resection with extended
lymphadenectomy may be justified in selected patients [4].
However, only a few patients have any benefit from exten-
sive dissection and the key factors in subsets of patients with
PALNM that may experience oncologic benefits from
PALND remain unknown.
The description of prognostic factors for pathological
PALNM allows the identification of patients who may ben-
efit from PALND while sparing other patients from the mor-
bidity of extensive lymphadenectomy. The aim of this study
was to analyze the prognostic factors and to develop a prog-
nostic model of extraregional lymphadenectomy for colon
cancer with isolated PALNM. 
Materials and Methods
1. Patients
From our prospectively collected database, a total of 1,082
patients who underwent curative surgery for colonic adeno-
carcinoma with pathological lymph node metastasis at Sev-
erance Hospital, Yonsei University, Seoul, South Korea, were
included. With the following exclusion criteria, 49 patients
who received a pathologic diagnosis of isolated synchronous
PALNM were included in this study: (1) distant metastases
other than to PALNM, (2) lateral pelvic lymph node metas-
tasis, and (3) nodal metastasis above the renal vessels. Clin-
icopathologic data including age, sex, body mass index,
location of tumor, preoperative carcinoembryonic antigen
(CEA), postoperative chemotherapy, pathologic tumor and
nodal stage, tumor differentiation, the numbers of total and
positive PALN, and survival data were obtained. 
2. Preoperative staging and treatment
Preoperative staging evaluation was performed using
chest X-ray and abdominal and chest computed tomography
(CT) scan. For PALNM diagnosis, abdominal CT scan was
mainly used and positron emission tomogram (PET) was
performed in selected cases where the diagnosis of PALNM
by CT was uncertain. We considered a PALN to be radiolog-
ically positive if a lymph node at the region between the left
renal vein and the bilateral common iliac vessels was 0.5 cm
at the short-axis diameter, with spiculated borders or show-
ing a mottled heterogenic pattern according to the preoper-
ative abdominal CT scan or had fludeoxyglucose uptake on
PET-CT. In addition to the standard extent of lymph node
dissection, all lymphovascular tissues along the aortocaval
area between the left renal vein and the bilateral common
iliac vessels were removed in patients with advanced colon
cancer with radiologically suspected metastatic PALN. Post-
operative chemotherapy (5-fluorouracil/leucovorin regimen
or oxaliplatin, folinic acid and 5-fluorouracil [FOLFOX]) was
administered 3-4 weeks after surgery for 6 months.
3. Evaluation parameters and statistical analyses
The classification system of the AJCC sixth edition was
used to determine pathological tumor depth (pT), the num-
ber of metastasized lymph nodes (pN), and cancer stage.
PALN was defined as the presence of involved lymph nodes
in the region between the bilateral common iliac vessels and




Age, mean±SD (yr) 57.5±11.5
Body mass index, mean±SD (kg/m2) 23.7±2.8
Location of tumor
Cecum 1 (2.0)
Ascending colon 5 (10.2)
Descending colon 5 (10.2)
Sigmoid colon 38 (77.6)
Preoperative CEA, mean±SD (ng/mL) 23.7±37.4
POD 7 CEA, mean±SD (ng/mL) 7.4±13.0






Well differentiated 4 (8.2)
Moderately differentiated 34 (69.4)
Poorly differentiated 6 (12.2)
Mucinous 5 (10.2)
Total retrieved LNs, mean±SD 38.2±22.0
Positive retrieved LNs, mean±SD 15.6±15.1 
Total para-aortic LNs, mean±SD 6.9±5.2
Positive para-aortic LNs, mean±SD 3.9±4.0
Table 1. Characteristics of colon cancer patients with
para-aortic lymph node metastasis
SD, standard deviation; CEA, carcinoembryonic antigen;
POD, postoperative day; LN, lymph node.
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left renal vein. All patients received postoperative clinical 
examinations, measurement of serum CEA levels, and chest 
X-rays every 3 months, and a chest/abdominal CT every 6
months over a period of 3 years. After 3 years, the follow-up
interval was changed to 6 months. Recurrence was defined
as the presence of a histologically and/or radiologically con-
firmed tumor. Overall survival (OS) time was calculated
from the date of surgery to the date of the latest follow-up
visit or the date of death due to any cause, and disease-free
survival (DFS) time was defined as the time from surgery to
any type of recurrence. Patients who died from other causes
or were alive without progression or recurrence at the most
recent follow-up were treated as censored in the analysis of
DFS time. Five-year survival rate was determined by the 
Kaplan-Meier method, and the log-rank test was used to
compare survival rates among subgroups. The log-rank test
was used for univariate analysis and independent prognostic
factors were identified by multivariate analysis using the Cox
proportional hazards model to calculate hazard ratios (HR).
Age ( 60 or > 60 years), sex (female or male), tumor depth
(T1, T2 or T3, T4), number of positive PALNs ( 7 or > 7), and
preoperative CEA level ( 5 or > 5) were included as covari-
ates. The results of the Cox model analysis are reported using
HR and 95% confidence intervals (CI). All statistical tests
were performed using IBM SPSS ver. 21.0 (IBM Corp., 
Armonk, NY). Data are expressed as means with standard
deviation. p-values of less than 0.05 were defined to indicate
a statistically significant difference.  
4. Ethical statement
The study was approved by the Institutional Review Board
of Severance Hospital (IRB No. 2017-2432-001) and per-
formed in accordance with the principles of the Declaration
of Helsinki. The informed consent was waived.
Results
1. Patient characteristics
Table 1 summarizes the characteristics of the 49 patients
with pathologically positive PALN who underwent PALND
for colonic cancer. The mean age was 57.5±11.5 years; 20 
patients (40.8%) were women and 29 (59.2%) men. Body
mass index was 23.7±2.8. One tumor (2.0%) was located in
the cecum, five (10.2%) in the ascending colon, five (10.2%)
in the descending colon, and 38 (77.6%) in the sigmoid colon.
The mean CEA level before the operation was 23.7±37.4
ng/mL and the CEA level measured 7 days after curative 
resection was 7.4±13.0 ng/mL. Of the total 49 patients, 
47 (95.9%) received chemotherapy after curative resection.
Table 2. Prognostic factors of 5-year survival by univariate analysis 
Prognostic factor No. (n=49) OS (%) p-value DFS (%) p-value
Age (yr)
 60 28 30.8 0.813 19.8 0.830
> 60 21 31.4 28.6
Sex
Male 29 28.5 0.257 22.2 0.872
Female 20 35.0 25.0
Tumor stage
T1 and T2 6 33.3 0.954 33.3 0.584
T3 and T4 43 30.7 21.7
Histology
Well and moderately 43 31.7 0.590 22.5 0.667
Poorly and mucinous 6 25.0 33.3
Positive retrieved PALNs
 7 42 36.5 0.010 27.5 0.027
> 7 7 14.3 14.3
Preoperative CEA
 5 19 46.3 0.122 41.4 0.039
> 5 30 21.5 11.7
OS, overall survival; DFS, disease-free survival; PALN, para-aortic lymph node; CEA, carcinoembryonic antigen.
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2. Pathologic outcomes
Pathologic characteristics of the tumors are summarized
in Table 1. There was one T2 tumor (2.0%), 43 T3 tumors
(87.8%), and five T4 tumors (10.1%). The moderately differ-
entiated type (69.4%) was the most common histological
type, followed by poorly differentiated (12.2%), mucinous
(10.2%), and well differentiated (8.2%). The mean numbers
of total and positive lymph nodes were 38.2±22.0 and
15.6±15.1, respectively. The mean numbers of total harvested
and metastatic PALNs were 6.9±5.2 and 3.9±4.0, respectively. 
Fig. 1.  (A) Five-year overall survival (OS) of patients with para-aortic lymph node metastasis (PALNM) according to the
number of positive para-aortic lymph node (PALN). (B) Five-year disease-free survival (DFS) according to the number of
positive PALN. (C) Five-year OS according to the preoperative carcinoembryonic antigen (CEA) level. (D) Five-year DFS
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3. Univariate and multivariate survival analyses of prog-
nostic factors
The median survival time was 37 months (range, 6 to 169
months). Five-year OS and DFS rates were 33.9% and 26.5%,
respectively. Table 2 summarizes the univariate analysis.
Univariate analyses revealed that the number of positive
PALN and the preoperative CEA level were significantly 
associated with OS and DFS (Table 2). Fig. 1 describes patient
survival according to the number of positive PALN and pre-
operative CEA level. The 5-year OS and DFS rates were
higher in patients with  7 positive PALN (36.5% and 27.5%)
than in those with > 7 PALN (14.3% and 14.3%; p=0.010 and
p=0.027, respectively) (Fig. 1A and B). Preoperative CEA
level > 5 also adversely affected patient prognosis, with a
lower 5-year OS and DFS rate at 21.5% and 11.7% observed
in patients with CEA level > 5 compared to those with CEA
level  5 (collectively at 46.3% and 41.4%, p=0.122 and
Fig. 1.  (Continued from the previous page) (E) Five-year OS according to the prognostic model. (F) Five-year DFS according to
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Time after operation (mo)
362412 6048
p=0.015
CEA ≤ 5 and PALNM ≤ 7 (n=17), 53.3%
CEA ≤ 5 and PALNM > 7 or
CEA > 5 and PALNM ≤ 7 (n=27), 13.2%
CEA > 5 and PALNM > 7 (n=5), 0%
Prognostic factor
Overall survival Disease-free survival
HR (95% CI) p-value HR (95% CI) p-value
Age
> 60 yr vs.  60 yr 0.885 (0.434-1.806) 0.738 1.049 (0.534-2.061) 0.889
Sex
Female vs. male 0.745 (0.353-1.571) 0.440 0.859 (0.416-1.773) 0.682
Tumor stage
T3 and T4 vs. T1 and T2 0.816 (0.276-2.413) 0.713 1.108 (0.382-3.217) 0.850
Histology
Poorly and mucinous vs. well and moderately 1.660 (0.553-4.986) 0.366 1.299 (0.443-3.807) 0.634
Positive retrieved PALNs
> 7 vs.  7 3.291 (1.309-8.275) 0.011 2.484 (0.993-6.211) 0.052
Preoperative CEA
> 5 vs.  5 1.575 (0.738-3.361) 0.241 1.953 (0.940-4.057) 0.073
Table 3. Prognostic factors of 5-year survival by multivariate analysis 
HR, hazard ratio; CI, confidence interval; PALN, para-aortic lymph node; CEA, carcinoembryonic antigen.
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p=0.039) (Fig. 1C and D). Multivariate analysis showed the
number of positive PALN (HR, 3.291; 95% CI, 1.309 to 8.275;
p=0.011) was an independent prognostic factor for OS and
the number of positive PALN (HR, 2.484; 95% CI, 0.993 to
6.211; p=0.052) and preoperative CEA level (HR, 1.953; 95%
CI, 0.940 to 4.057; p=0.073) as marginally independent prog-
nostic factors for DFS (Table 3). According to our prognostic
model with two prognostic factors, the 5-year OS and DFS
rate increased to 59.3% and 53.3%, respectively, in patients
with  7 positive PALN and a CEA level  5 (Fig. 1E and F).
The 5-year OS and DFS rates of patients with CEA level  5
and > 7 positive PALN or CEA level > 5 and  7 positive
PALN were 24.9% and 13.2%, respectively. The 5-year OS
and DFS rates of patients with CEA level > 5 and > 7 positive
PALN were 0% and 0%, respectively.
Discussion
In the context of hepatic metastasis in colorectal cancer, 
upfront primary tumor resection with metastasectomy is rec-
ommended in surgically amenable metastasis (lesions  4,
absence of bilobar metastasis, and radiologically negative
periportal lymph nodes) [5]. In the current prognostic analy-
ses of 49 colon cancer patients with pathological PALNM
who underwent extraregional lymphadenectomy, our results
show that PALND may be justified in highly selected 
patients. We have found that an elevated preoperative CEA
level and a greater number of positive PALN indicates a poor
survival outcome and the subgroup of patients with  7 pos-
itive PALN and a CEA level  5 might still benefit from sur-
gery. Thus, systematic PALND should be considered as a
treatment option in those patients.
Ogura et al. [6] attempted to establish a prognostic model
for visible PALNM with CRC and reported that lymphovas-
cular invasion, nodal status, elevated preoperative CEA
level, and visible PALNs  10 mm were independent prog-
nostic factors for patients with visible PALNs, although that
model could not predict pathologic PALNM. Choi et al.  [1]
observed that the presence of two or fewer PALN metastases
was a good indication for PALND in 24 CRC patients with
isolated PALNM based on their univariate analysis; how-
ever, there were no data regarding pathologic PALNM and
no significant prognostic factors were identified by multi-
variate analysis. In our study, we tried to develop a prognos-
tic model using multivariate analysis for pathologically
identified PALNM after extensive lymphadenectomy in
colon cancer. 
Preoperative serum levels of the tumor marker CEA,
which represent serum tumor burden, are of prognostic sig-
nificance. CEA levels  5.0 ng/mL have an adverse effect on
survival that is independent of tumor stage [7-9]. Hokuto et
al. [10] reported that a serum CEA level of  20 ng/mL was
one of the prognostic factors for DFS in patients with  4 col-
orectal liver metastases and a systematic review assessing
prognostic factors for patients undergoing lung metastasec-
Fig. 2. Suggested treatment strategy for colon cancer with isolated para-aortic lymph node metastasis. PALNM, para-aortic
lymph node metastasis; PTR, primary tumor resection; PALND, para-aortic lymph node dissection; CTX, chemotherapy.
Preoperatively diagnosed colon cancer with isolated PALNM








PTR+PALND PTR only or
PTR+PALND
Palliative CTX
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tomy showed that a prethoracotomy associated elevation in
CEA level was associated with poor survival [11]. In this
study, elevated preoperative CEA level was identified to be
an independent risk predictor for oncologic outcomes, which
is consistent with the prior results in the literature. 
Lymph node involvement is one of the strongest predictors
of outcome following surgical resection of CRC [12-16].
Moreover, we found that the long-term oncologic outcomes
were significantly better in the regional lymph node metas-
tasis group than in the PALNM group, which means that the
location of the metastatic lymph node also matters [4]. In the
present study, the 5-year survival rate was poor in patients
with a large number of positive PALN, which was identified
as an independent prognostic factor after PALND. Thus,
PALND should be considered as a treatment option in 
patients with a relatively smaller number of infiltrated lymph
nodes. 
The availability of increasingly effective systemic chemo-
therapy has prompted interest in preoperative or neoadju-
vant chemotherapy for stage IV CRC [17]. Neoadjuvant
chemotherapy might play a role in evaluating the natural his-
tory of metastatic disease, which then enables the surgeon to
decide whether to proceed with surgery or to continue pal-
liative chemotherapy in cases of CRC with PALNM. An 
expert review further emphasized the role of neoadjuvant
chemotherapy in the selection of candidates for PALND 
because tumor regression after treatment may imply a favor-
able biology, thereby selecting for patients more likely to
benefit from PALND [18]. Currently, we have discussed
treatment plans based on a multidisciplinary approach for
these patients and most of them were recommended to 
receive upfront systemic chemotherapy followed by surgical
resection for both the primary tumor and extraregional
lymph nodes (PALN).
A multimodality approach including perioperative chemo-
therapy may be needed to improve survival of patients with
colon cancer with isolated PALNM and the treatment strat-
egy should be individualized according to the characteristics
of the disease. Our results suggest that upfront primary
tumor resection with extended lymphadenectomy may be
justified in patients with low CEA levels and less extensive
PALNM, based on our prognostic model (Fig. 2). Neoadju-
vant chemotherapy can be an initial targeted treatment for
colon cancer with an elevated CEA level or extensive
PALNM. Primary tumor resection with or without PALND
should be performed after neoadjuvant treatment based on
tumor response. Treatment of progressive disease with ele-
vated CEA level and extensive PALNM even after neoadju-
vant chemotherapy needs to be converted to palliative
chemotherapy with other additional treatments such as 
intensity-modulated radiotherapy, tomotherapy, and robotic
linear accelerators.
There are several limitations to this study, including a sin-
gle institutional experience, the small sample size due to the
rarity of this metastatic pattern, and its retrospective analysis.
In addition, new biologic chemotherapeutic regimens were
not used in most of the patients, and therefore, we could not
analyze the prognostic factors after neoadjuvant treatment. 
PALND might be beneficial in carefully selected patients
with low CEA levels and less extensive PALNM.
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
Acknowledgments
This work was supported by the National Research Foundation
of Korea (NRF) Grant funded by the Korea Government (MSIP) (No.
2014R1A5A2010008).
This work was supported by the Student’s Association of the
Graduate School of Yonsei University funded by the Graduate
School of Yonsei University.
1. Choi PW, Kim HC, Kim AY, Jung SH, Yu CS, Kim JC. Exten-
sive lymphadenectomy in colorectal cancer with isolated para-
aortic lymph node metastasis below the level of renal vessels.
J Surg Oncol. 2010;101:66-71.
2. Gagniere J, Dupre A, Chabaud S, Peyrat P, Meeus P, Rivoire
M. Retroperitoneal nodal metastases from colorectal cancer:
curable metastases with radical retroperitoneal lymphadenec-
tomy in selected patients. Eur J Surg Oncol. 2015;41:731-7.
3. Greene FL. The American Joint Committee on Cancer: updat-
ing the strategies in cancer staging. Bull Am Coll Surg.
2002;87:13-5.
4. Bae SU, Han YD, Cho MS, Hur H, Min BS, Baik SH, et al. 
Oncologic outcomes of colon cancer patients with extrare-
gional lymph node metastasis: comparison of isolated
paraaortic lymph node metastasis with resectable liver metas-
tasis. Ann Surg Oncol. 2016;23:1562-8.
5. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of sur-
gical therapy for hepatic colorectal metastases: is there a limit?
References
Cancer Res Treat. 2018;50(3):712-719
718 CANCER  RESEARCH  AND  TREATMENT
J Clin Oncol. 2005;23:8490-9.
6. Ogura A, Akiyoshi T, Takatsu Y, Nagata J, Nagasaki T, Kon-
ishi T, et al. The significance of extended lymphadenectomy
for colorectal cancer with isolated synchronous extraregional
lymph node metastasis. Asian J Surg. 2017;40:254-61.
7. Wiggers T, Arends JW, Volovics A. Regression analysis of
prognostic factors in colorectal cancer after curative resections.
Dis Colon Rectum. 1988;31:33-41.
8. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carci-
noembryonic antigen monitoring after curative resection for
colorectal cancer: clinical significance of the preoperative level.
Ann Surg Oncol. 2009;16:3087-93.
9. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pra-
gatheeshwar KD, Pingpank JF, et al. C-stage in colon cancer:
implications of carcinoembryonic antigen biomarker in stag-
ing, prognosis, and management. J Natl Cancer Inst. 2011;103:
689-97.
10. Hokuto D, Nomi T, Yamato I, Yasuda S, Obara S, Yoshikawa
T, et al. The prognosis of liver resection for patients with four
or more colorectal liver metastases has not improved in the
era of modern chemotherapy. J Surg Oncol. 2016;114:959-65.
11. Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Ger-
vaz P. Risk factors for survival after lung metastasectomy in
colorectal cancer patients: a systematic review and meta-
analysis. Ann Surg Oncol. 2013;20:572-9.
12. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton
C, Benson AB 3rd, et al. Impact of number of nodes retrieved
on outcome in patients with rectal cancer. J Clin Oncol.
2001;19:157-63.
13. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA.
Lymph node evaluation and survival after curative resection
of colon cancer: systematic review. J Natl Cancer Inst. 2007;99:
433-41.
14. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald
JS, Catalano PJ, et al. Colon cancer survival is associated with
increasing number of lymph nodes analyzed: a secondary sur-
vey of intergroup trial INT-0089. J Clin Oncol. 2003;21:2912-9.
15. Jang KU, Kim CW, Kim KH, Lim SB, Yu CS, Kim TW, et al.
Prognostic factors in terms of the number of metastatic nod-
ules in patients with colorectal cancer liver metastases. Ann
Coloproctol. 2016;32:92-100.
16. Park SJ, Lee KY, Kim SY. Clinical significance of lymph node
micrometastasis in stage I and II colon cancer. Cancer Res
Treat. 2008;40:75-80.
17. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM,
Rougier P, et al. Perioperative FOLFOX4 chemotherapy and
surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC 40983): long-term results of a
randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:
1208-15.
18. Albandar MH, Cho MS, Bae SU, Kim NK. Surgical manage-
ment of extra-regional lymph node metastasis in colorectal
cancer. Expert Rev Anticancer Ther. 2016;16:503-13.
Sung Uk Bae, Para-aortic Lymph Node Metastasis in Colon Cancer
VOLUME 50 NUMBER 3 JULY 2018  719
